Holen Sie sich die Stockscreener-App
2.35
2.89%
-0.07
Minerva Neurosciences Inc Aktie (NERV) Neueste Nachrichten
Anthony Aliquo Net Worth (2026) - GuruFocus
Minerva Neurosciences Inc. Stock Grades | NERV - Barron's
Minerva Neurosciences Inc Share PriceNERV, RNS News, Articles, Quotes, & Charts (NASDAQ:NERV) - Proactive financial news
Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to S&P Global BMI Index - marketscreener.com
Minerva Neurosciences at Cantor conference: roluperidone reset By Investing.com - Investing.com Nigeria
Minerva Neurosciences at Cantor conference: roluperidone reset By Investing.com - Investing.com Canada
Minerva Neurosciences Inc. (NERV) Q2 2026 Earnings: Wider-Than-Expected EPS Loss Highlights Capital-Intensive Pre-Commercial StageRevenue Breakdown Analysis - siam.in
Minerva Neurosciences Inc. (NERV) Q2 2026 Earnings: Wider-Than-Expected EPS Loss Highlights Capital-Intensive Pre-Commercial StageEPS Consistency Score - dars.gov.et
Minerva Neurosciences Inc. (NERV) Q2 2026 Earnings: Wider-Than-Expected EPS Loss Highlights Capital-Intensive Pre-Commercial StageEarnings Seasonality - dars.gov.et
Minerva Neurosciences Inc. (NERV) Q2 2026 Earnings: Wider-Than-Expected EPS Loss Highlights Capital-Intensive Pre-Commercial StageGuidance Accuracy Score - https://www.dars.gov.et/
Minerva Neurosciences Inc. (NERV) Q2 2026 Earnings: Wider-Than-Expected EPS Loss Highlights Capital-Intensive Pre-Commercial StageAnalyst Earnings Estimate - dars.gov.et
Minerva Neurosciences to Participate in Two Upcoming Investor Conferences - Investing News Network
Minerva Neurosciences to Participate in Two Upcoming Investor Conferences - kommunikasjon.ntb.no
Minerva Neurosciences to Participate in Two Upcoming Investor Conferences - Yahoo Finance
Minerva Neurosciences to Participate in Two Upcoming Investor Conferences - The Manila Times
Minerva (NERV): Loses 0.62% to Close at $4.81 in Latest Trading; Level Watch: the $4.57 to $5.05 Range Remains in Focus for the Current SessionBearish Pattern Stocks - careplusvn.com
Minerva Neurosciences Inc (NASDAQ: NERV) Share Price, NERV Stock News, NERV Share Price & Updates - Kalkine
Balyasny Asset Management L.P. Expands Stake in Minerva Neurosciences Inc (NERV) - GuruFocus
Minerva Neurosciences (NASDAQ: NERV) COO holds 20,872 shares, 750K and 680K options - Stock Titan
NERV Upgraded by Jefferies -- Price Target Raised to $10.00 - GuruFocus
Minerva Neurosciences (NASDAQ:NERV) Downgraded to Strong Sell Rating by Zacks Research - MarketBeat
Minerva Neurosciences, Inc (NASDAQ:NERV) Given Consensus Recommendation of "Reduce" by Brokerages - marketbeat.com
Balyasny Asset Management (NERV) discloses 9.99% Minerva Neurosciences ownership via shares and warrants - Stock Titan
Jefferies Upgrades Minerva Neurosciences(NERV.US) to Buy Rating, Raises Target Price to $10 - Moomoo
Jefferies upgrades Minerva Neurosciences stock rating on regulatory pathway By Investing.com - Investing.com Canada
Jefferies upgrades Minerva Neurosciences stock rating on regulatory pathway By Investing.com - Investing.com India
Jefferies upgrades Minerva Neurosciences stock rating on regulatory pathway By Investing.com - Investing.com UK
Jefferies Maintains Minerva Neurosciences(NERV.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Farallon group discloses 9.7% Minerva Neurosciences (NERV) holding via shares and warrants - Stock Titan
Minerva Neurosciences (NERV) Advances to $3.99, Holding Support as Resistance at $4.19 LoomsHot Stock Picks - vinanet.vn
Minerva Neurosciences (NERV) Advances to $3.99, Holding Support as Resistance at $4.19 LoomsNHNL Ratio - careplusvn.com
Minerva Neurosciences (NERV) Plunges 9% to $3.92: Critical Support Level in FocusTotal Put Call - siam.in
Minerva Neurosciences Elevates Aliquo to Accounting Leadership - TipRanks
Minerva Neurosciences (NERV) elevates Anthony Aliquo to chief accounting officer role - Stock Titan
HC Wainwright Has Bearish Estimate for NERV Q3 Earnings - MarketBeat
H.C. Wainwright Maintains Minerva Neurosciences(NERV.US) With Hold Rating, Maintains Target Price $7 - Moomoo
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Minerva Neurosciences (NERV) and Zymeworks (ZYME) - The Globe and Mail
Minerva Neurosciences (NASDAQ:NERV) Upgraded at Wall Street Zen - MarketBeat
Minerva Neurosciences (NASDAQ:NERV) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat
Form 8K Minerva Neurosciences Inc For: 7 August By Investing.com - Investing.com Nigeria
Form 8K Minerva Neurosciences Inc For: 7 August By Investing.com - Investing.com South Africa
Minerva Neurosciences Q2 adjusted EPS beats estimates on warrant gain - scanx.trade
Minerva Neurosciences Provides Second Quarter 2026 Financial Results And Business Updates - TradingView
Minerva Neurosciences, Inc. Q2 2026: Net income $17.47M, EPS $(0.14) — 10-Q Summary - TradingView
Minerva Neurosciences (NASDAQ: NERV) logs $107.9M loss but holds $75.4M cash - Stock Titan
Form 8K Minerva Neurosciences Inc For: 7 August By Investing.com - Investing.com Canada
Minerva Neurosciences posts Q2 2026 results: GAAP net income $17.5M; cash & equivalents $75.4M - TradingView
Minerva Neurosciences: Q2 Earnings Snapshot - marketscreener.com
Minerva Neurosciences: Q2 Earnings Snapshot - Barchart.com
Minerva Neurosciences reports $17.5 million Q2 net income as Phase 3 trial continues - Quiver Quantitative
4.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):